IL-7 Engineering & Application Development Services
Creative Biolabs provides cutting-edge solutions for researchers in immunotherapy. We deliver custom-engineered, stabilized IL-7 muteins and targeted fusion proteins that overcome the limitations of native cytokines. Clients gain a significantly de-risked and functionally superior therapeutic candidate, complete with robust preclinical characterization data and an optimized vector sequence, ready for advanced in vivo studies and partnership discussions. Our goal is to accelerate your preclinical oncology program by providing validated, best-in-class assets.
Introduction What We Can Offer Types of Our Services Why Creative Biolabs Customer Reviews FAQs Related Services Contact Us
Engineered IL-7 for Cancer Immunotherapy
IL-7 is a crucial γ-chain cytokine essential for T-cell lymphopoiesis and the maintenance of naive and memory T-cell populations. Native recombinant IL-7's therapeutic use is constrained by rapid systemic clearance, often leading to insufficient concentration in the tumor microenvironment. Through advanced protein engineering, we generate long-acting IL-7 variants (such as Fc-fusions) and targeted constructs that significantly enhance T-cell proliferation and persistence. Published Data confirm that these engineered variants not only match the potency of native IL-7 but also provide superior durability and a favorable Treg-sparing profile.
Inquire Now to Explore Our Expertise.
Fig.1 IL-7 and IL-7R have both pro- and anti-tumor functions. 1
What We Can Offer
Customized Mutein Design
We specialize in tailored hyper-agonistic IL-7 Mutein generation, achieving maximal T-cell expansion at ultra-low concentrations. Our rational design minimizes Treg bias and optimizes potency to meet your specific requirements.
Guaranteed PK Extension
Leverage our proprietary Hybrid Fc-fusion technology to reliably extend the serum half-life of your IL-7 candidate in preclinical models, drastically reducing dosing frequency and improving the drug's therapeutic window.
Precision Targeted Delivery
Access bespoke targeted delivery engineering, including the design and production of tumor-specific Immunocytokines or the highly efficacious IL-7/CCL19 co-secretion constructs for solid tumor applications.
Dose-Sparing Efficacy
Our engineered IL-7 variants provide a validated dose-sparing effect on co-administered cell therapies (CAR T/TILs), enhancing their persistence and function while lowering overall infused cell counts and reducing manufacturing costs.
Types of our IL-7 Engineering & Application Development Services
IL-7 Protein Engineering & Activity Optimization Service
This service focuses on modifying the IL-7 sequence itself to improve its fundamental properties—potency, stability, and selectivity. This is foundational for any successful IL-7 drug program.
Learn More →
Targeted IL-7 Delivery Engineering Services
This service specializes in conjugating the optimized IL-7 Mutein to a delivery vehicle to improve its pharmacokinetics and restrict its activity to the tumor site, maximizing the therapeutic index against solid tumors.
Learn More →
Highlights
Cytokine Engineering Leadership
Creative Biolabs is a recognized leader specializing exclusively in advanced cytokine engineering. Our deep focus overcomes the fundamental development hurdles of IL-7, giving your project a strategic advantage from the start.
Overcoming Key Hurdles
We possess the specialized expertise to defeat the major challenges in Interleukin-7 development: poor pharmacokinetics (PK) and non-specific systemic delivery. This precision engineering unlocks the full potential of IL-7.
Engineering Therapeutic Function
We move beyond simple protein production. Our mission is to engineer genuine therapeutic function, ensuring your IL-7 asset is optimized for potency, stability, and targeted action, which maximizes clinical relevance.
Minimized Systemic Risk
Our critical advantage lies in engineering IL-7 to minimize systemic risk and maximize on-site efficacy. This strategy successfully widens the therapeutic window, ensuring safer and more effective clinical outcomes.
Ready to accelerate your immunotherapy pipeline? Talk to an expert now.
Customer Reviews
-
Dose-Sparing Benefit
Using Creative Biolabs' services in our research has significantly facilitated lowering the required dose of our CAR T cell product. The long-acting Fc-fusion candidate demonstrated superior expansion and persistence compared to native IL-7, allowing us to hit the efficacy endpoint with five times fewer infused cells. - Dr. K**n L.
-
Persistence and Cytotoxicity
The targeted IL-7 delivery engineering service provided a secreted IL-7/CCL19 CAR T vector that remarkably improved the functional activity of our T-cells. We observed better protection against tumor rechallenge, confirming the potent anti-exhaustion and memory-boosting effects compared to traditional IL-15 co-culture methods. - Pr. E*k T.
FAQs
Q:
How does Creative Biolabs' engineered IL-7 compare to IL-2, and is the toxicity profile better?
A:
Our engineered IL-7 is functionally distinct from IL-2. While both expand T-cells, our optimized IL-7 variants preferentially promote effector T-cell survival and, crucially, do not promote the expansion of immunosuppressive regulatory T cells (Tregs) in the same manner as IL-2. This selective expansion leads to a significantly better therapeutic index and lower risk of systemic inflammatory toxicity.
Q:
I am developing a CAR T-cell therapy; at what stage should I introduce your IL-7 service?
A:
Ideally, you should engage our services during the preclinical candidate selection phase. Integrating a long-acting IL-7 variant early allows for immediate assessment of the potential for dose-sparing and improved T-cell persistence ex vivo and in vivo.
Related Services
Next Immunocytokine Engineering Development
Beyond IL-7, we offer engineering for other critical cytokines (e.g., IL-2, IL-12, IL-15) and fusion proteins, allowing you to create complex, multi-functional therapeutic agents.
Learn More →
TCR Design Construction and Plasmid GLP Production
Comprehensive services for TCR discovery, affinity maturation, and validation. We ensure your TCR candidate exhibits superior specificity and potency for oncology targets.
Learn More →
How to Contact Us
Creative Biolabs is dedicated to advancing your therapeutic programs by providing highly engineered IL-7 solutions that overcome the historical limitations of cytokine therapy. Whether you require a hyper-potent, long-acting mutein or a complex targeted delivery system, our scientific team is ready to deliver validated, research-ready candidates. Please contact us.
Reference
-
Wang, Chunli et al. "The Role of IL-7 and IL-7R in Cancer Pathophysiology and Immunotherapy." International journal of molecular sciences vol. 23,18 10412. 8 Sep. 2022. Distributed under an Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/ijms231810412
For Research Use Only | Not For Clinical Use
